Accessibility Menu
Citius Pharmaceuticals Stock Quote

Citius Pharmaceuticals (NASDAQ: CTXR)

$1.57
(-6.5%)
-0.11
Price as of October 22, 2025, 4:00 p.m. ET

KEY DATA POINTS

Current Price
$1.57
Daily Change
(-6.5%) $0.11
Day's Range
$1.5 - $1.76
Previous Close
$1.57
Open
$1.76
Beta
1.01
Volume
1,075,261
Average Volume
721,798
Market Cap
26.7M
Market Cap / Employee
$1.57M
52wk Range
$0.65 - $12.84
Revenue
-
Gross Margin
-
Dividend Yield
N/A
EPS
-$4.96
CAPs Rating
-
Industry
Pharmaceuticals

The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More

Citius Pharmaceuticals Return vs. S&P

1 Year5 Year5 Year AnnualizedSince IPO
CTXR-82.98%-94.49%-44%-100%
S&P+14.5%+93.32%+14.09%+244%

Citius Pharmaceuticals Company Info

Citius Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of critical care products, with a focus on oncology, anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. Its products include I/ONTAK, Mino-Lok, Halo-Lido, Mino-Wrap, and Novecite. The company was founded by Ralph Montrone on January 23, 2007 and is headquartered in Cranford, NJ.

News & Analysis

Financial Health

General

Q2 2025YOY Change
Revenue$0.00M0.0%
Gross Profit-$0.04M21.7%
Market Cap$17.77M-80.9%
Market Cap / Employee$0.77M0.0%
Employees230.0%
Net Income-$9.20M13.0%
EBITDA-$8.75M17.3%

Currently no data to display

Revenue Growth Rate

Currently no data to display.

Earnings Per Share Growth Rate

Currently no data to display.

Assets

Q2 2025YOY Change
Net Cash$6.09M-66.0%
Inventory17.20.0%

Liabilities

Q2 2025YOY Change
Long Term Debt$0.77M808.4%
Short Term Debt$1.11M373.2%

Ratios

Q2 2025YOY Change
Return On Assets-35.83%1.1%
Return On Invested Capital-38.41%0.3%

Cash Flow

Q2 2025YOY Change
Free Cash Flow-$5.41M35.4%
Operating Free Cash Flow-$5.41M35.4%

Valuation

MetricQ3 2024Q4 2024Q1 2025Q2 2025YoY Change
Price to Book1.290.410.180.23-80.38%
Price to Tangible Book Value133.54-0.90-0.31-0.34-100.15%
Enterprise Value to EBITDA-8.34-3.26-1.48-1.81-77.38%
Return on Equity-48.6%-52.9%-60.1%-53.4%27.92%
Total Debt$0.26M$0.20M$0.93M$1.88M488.00%

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.